{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:39:35Z","timestamp":1792805975484,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,22]],"date-time":"2021-03-22T00:00:00Z","timestamp":1616371200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,22]],"date-time":"2021-03-22T00:00:00Z","timestamp":1616371200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81370308"],"award-info":[{"award-number":["81370308"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Trimethylamine-N-oxide (TMAO) can activate platelets and increase thrombosis risk in clinical and experimental models. Meanwhile, the patients with coronary artery disease have higher serum TMAO level. However, it remains unknown whether Clopidogrel Resistance (CR) could be attributed to TMAO. The present study aimed investigate the effects of TMAO on clopidogrel in ischemia and reperfusion (IR) model in rats. Clopidogrel could (1) promote the production of platelets, induce an increase in the platelet-larger cell ratio; (2) prolong the tail bleeding time; (3) reduce platelet aggregation function, induced by ADP, and alleviate myocardial thrombus burden. TMAO could partially offset the effects of clopidogrel and induce CR. Thus, the present study demonstrated that circulating TMAO could reduce the inhibitory effects of clopidogrel on platelet aggregation. TMAO may be a potential mediator of clopidogrel resistance.<\/jats:p>","DOI":"10.1038\/s41598-021-85950-8","type":"journal-article","created":{"date-parts":[[2021,3,22]],"date-time":"2021-03-22T11:03:43Z","timestamp":1616411023000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["TMAO: a potential mediator of clopidogrel resistance"],"prefix":"10.1038","volume":"11","author":[{"given":"Ruisong","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenwen","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaorong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,22]]},"reference":[{"key":"85950_CR1","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1016\/j.jacc.2007.07.051","volume":"50","author":"PA Gurbel","year":"2007","unstructured":"Gurbel, P. A., Becker, R. C., Mann, K. G., Steinhubl, S. R. & Michelson, A. D. Platelet function monitoring in patients with coronary artery disease. J. Am. Coll. Cardiol. 50, 1822\u20131834 (2007).","journal-title":"J. Am. Coll. Cardiol."},{"key":"85950_CR2","first-page":"213","volume":"39","author":"A Kastrati","year":"2017","unstructured":"Kastrati, A. et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European. Eur. Heart J. 39, 213\u2013260 (2017).","journal-title":"Eur. Heart J."},{"key":"85950_CR3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/1074248417724869","volume":"23","author":"MA Esteve-Pastor","year":"2018","unstructured":"Esteve-Pastor, M. A. et al. Temporal trends in the use of antiplatelet therapy in patients with acute coronary syndromes. J. Cardiovasc. Pharmacol. Ther. 23, 57\u201365 (2018).","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"85950_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12959-019-0197-5","volume":"17","author":"EMK Warlo","year":"2019","unstructured":"Warlo, E. M. K., Arnesen, H. & Seljeflot, I. A brief review on resistance to P2Y12 receptor antagonism in coronary artery disease. Thromb. J. 17, 11 (2019).","journal-title":"Thromb. J."},{"key":"85950_CR5","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1177\/0897190015615900","volume":"29","author":"CS Oliphant","year":"2016","unstructured":"Oliphant, C. S., Trevarrow, B. J. & Dobesh, P. P. Clopidogrel response variability: Review of the literature and practical considerations. J. Pharm. Pract. 29, 26\u201334 (2016).","journal-title":"J. Pharm. Pract."},{"key":"85950_CR6","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1136\/hrt.2009.171488","volume":"96","author":"T Gremmel","year":"2010","unstructured":"Gremmel, T. et al. Calcium-channel blockers decrease clopidogrel-mediated platelet inhibition. Heart 96, 186\u2013189 (2010).","journal-title":"Heart"},{"key":"85950_CR7","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s002280050706","volume":"55","author":"M Katoh","year":"2000","unstructured":"Katoh, M., Nakajima, M., Shimada, N., Yamazaki, H. & Yokoi, T. Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: Prediction of in vivo drug\u2013drug interactions. Eur. J. Clin. Pharmacol. 55, 843\u2013852 (2000).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"85950_CR8","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1001\/jama.2009.1232","volume":"302","author":"AR Shuldiner","year":"2009","unstructured":"Shuldiner, A. R. et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. J. Am. Med. Assoc. 302, 849\u2013858 (2009).","journal-title":"J. Am. Med. Assoc."},{"key":"85950_CR9","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1016\/j.jacc.2010.02.031","volume":"55","author":"W Hochholzer","year":"2010","unstructured":"Hochholzer, W. et al. Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement. J. Am. Coll. Cardiol. 55, 2427\u20132434 (2010).","journal-title":"J. Am. Coll. Cardiol."},{"key":"85950_CR10","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1111\/bcp.12230","volume":"77","author":"D Trenk","year":"2014","unstructured":"Trenk, D. & Hochholzer, W. Genetics of platelet inhibitor treatment. Br. J. Clin. Pharmacol. 77, 642\u2013653 (2014).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"85950_CR11","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.amjcard.2012.12.013","volume":"111","author":"C Grosdidier","year":"2013","unstructured":"Grosdidier, C. et al. Effect of CYP2C19*2 and*17 genetic variants on platelet response to clopidogrel and prasugrel maintenance dose and relation to bleeding complications. Am. J. Cardiol. 111, 985\u2013990 (2013).","journal-title":"Am. J. Cardiol."},{"key":"85950_CR12","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1111\/jth.14234","volume":"16","author":"W Zhu","year":"2018","unstructured":"Zhu, W. et al. Flavin monooxygenase 3, the host hepatic enzyme in the metaorganismal trimethylamine N-oxide-generating pathway, modulates platelet responsiveness and thrombosis risk. J. Thromb. Haemost. 16, 1857\u20131872 (2018).","journal-title":"J. Thromb. Haemost."},{"key":"85950_CR13","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.cell.2016.02.011","volume":"165","author":"W Zhu","year":"2016","unstructured":"Zhu, W. et al. Gut microbial metabolite TMAO enhances platelet hyperreactivity and thrombosis risk. Cell 165, 111\u2013124 (2016).","journal-title":"Cell"},{"key":"85950_CR14","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1146\/annurev-nutr-071816-064732","volume":"37","author":"SH Zeisel","year":"2017","unstructured":"Zeisel, S. H. & Warrier, M. Trimethylamine N-oxide, the microbiome, and heart and kidney disease. Annu. Rev. Nutr. 37, 157\u2013181 (2017).","journal-title":"Annu. Rev. Nutr."},{"key":"85950_CR15","first-page":"348","volume":"2013","author":"D Gregg","year":"2013","unstructured":"Gregg, D. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. Yearb. Med. 2013, 348\u2013350 (2013).","journal-title":"Yearb. Med."},{"key":"85950_CR16","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/nm.3145","volume":"19","author":"RA Koeth","year":"2013","unstructured":"Koeth, R. A. et al. Intestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat. Med. 19, 576\u2013585 (2013).","journal-title":"Nat. Med."},{"key":"85950_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcm.2018.08.003","author":"GG Schiattarella","year":"2018","unstructured":"Schiattarella, G. G., Sannino, A., Esposito, G. & Perrino, C. Diagnostics and therapeutic implications of gut microbiota alterations in cardiometabolic diseases. Trends Cardiovasc. Med. https:\/\/doi.org\/10.1016\/j.tcm.2018.08.003 (2018).","journal-title":"Trends Cardiovasc. Med."},{"key":"85950_CR18","doi-asserted-by":"publisher","first-page":"e0143064","DOI":"10.1371\/journal.pone.0143064","volume":"10","author":"M Ruisong","year":"2015","unstructured":"Ruisong, M. et al. The protective role of interleukin-33 in myocardial ischemia and reperfusion is associated with decreased HMGB1 expression and up-regulation of the P38 MAPK signaling pathway. PLoS ONE 10, e0143064 (2015).","journal-title":"PLoS ONE"},{"key":"85950_CR19","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1160\/TH12-09-0709","volume":"109","author":"F Cesari","year":"2013","unstructured":"Cesari, F. et al. Reticulated platelets predict cardiovascular death in acute coronary syndrome patients: Insights from the AMI-florence 2 study. Thromb. Haemost. 109, 846\u2013853 (2013).","journal-title":"Thromb. Haemost."},{"key":"85950_CR20","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1111\/j.1538-7836.2009.03584.x","volume":"8","author":"SG Chu","year":"2010","unstructured":"Chu, S. G. et al. Mean platelet volume as a predictor of cardiovascular risk: A systematic review and meta-analysis. J. Thromb. Haemost. 8, 148\u2013156 (2010).","journal-title":"J. Thromb. Haemost."},{"key":"85950_CR21","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1016\/j.jacc.2004.05.033","volume":"44","author":"N Lakkis","year":"2004","unstructured":"Lakkis, N. et al. Reticulated platelets in acute coronary syndrome: A marker of platelet activity [3]. J. Am. Coll. Cardiol. 44, 2091\u20132093 (2004).","journal-title":"J. Am. Coll. Cardiol."},{"key":"85950_CR22","doi-asserted-by":"publisher","first-page":"e004947","DOI":"10.1161\/JAHA.116.004947","volume":"6","author":"Y Heianza","year":"2017","unstructured":"Heianza, Y., Ma, W., Manson, J. A. E., Rexrode, K. M. & Qi, L. Gut microbiota metabolites and risk of major adverse cardiovascular disease events and death: A systematic review and meta-analysis of prospective studies. J. Am. Heart Assoc. 6, e004947 (2017).","journal-title":"J. Am. Heart Assoc."},{"key":"85950_CR23","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/jcmm.13307","volume":"22","author":"J Qi","year":"2018","unstructured":"Qi, J. et al. Circulating trimethylamine N-oxide and the risk of cardiovascular diseases: A systematic review and meta-analysis of 11 prospective cohort studies. J. Cell. Mol. Med. 22, 185\u2013194 (2018).","journal-title":"J. Cell. Mol. Med."},{"key":"85950_CR24","doi-asserted-by":"publisher","first-page":"2948","DOI":"10.1093\/eurheartj\/ehx342","volume":"38","author":"GG Schiattarella","year":"2017","unstructured":"Schiattarella, G. G. et al. Gut microbe-generated metabolite trimethylamine-N-oxide as cardiovascular risk biomarker: A systematic review and dose\u2013response meta-analysis. Eur. Heart J. 38, 2948\u20132956 (2017).","journal-title":"Eur. Heart J."},{"key":"85950_CR25","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1161\/CIRCRESAHA.118.313142","volume":"123","author":"SM Skye","year":"2018","unstructured":"Skye, S. M. et al. Microbial transplantation with human gut commensals containing CUTC is sufficient to transmit enhanced platelet reactivity and thrombosis potential. Circ. Res. 123, 1164\u20131176 (2018).","journal-title":"Circ. Res."},{"key":"85950_CR26","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1038\/s41591-018-0128-1","volume":"24","author":"AB Roberts","year":"2018","unstructured":"Roberts, A. B. et al. Development of a gut microbe\u2013targeted nonlethal therapeutic to inhibit thrombosis potential. Nat. Med. 24, 1407\u20131417 (2018).","journal-title":"Nat. Med."},{"key":"85950_CR27","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/jth.14331","volume":"17","author":"TE van Mens","year":"2019","unstructured":"van Mens, T. E., B\u00fcller, H. R. & Nieuwdorp, M. Targeted inhibition of gut microbiota proteins involved in TMAO production to reduce platelet aggregation and arterial thrombosis: A blueprint for drugging the microbiota in the treatment of cardiometabolic disease?. J. Thromb. Haemost. 17, 3\u20135 (2019).","journal-title":"J. Thromb. Haemost."},{"key":"85950_CR28","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1080\/14017431.2019.1598571","volume":"53","author":"Y Wu","year":"2019","unstructured":"Wu, Y., Song, Y., Pan, Y., Gong, Y. & Zhou, Y. High on-clopidogrel platelet reactivity and chronic kidney disease: A meta-analysis of literature studies. Scand. Cardiovasc. J. 53, 55\u201361 (2019).","journal-title":"Scand. Cardiovasc. J."},{"key":"85950_CR29","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1161\/ATVBAHA.120.314139","volume":"40","author":"N Gupta","year":"2020","unstructured":"Gupta, N. et al. Targeted inhibition of gut microbial trimethylamine N-oxide production reduces renal tubulointerstitial fibrosis and functional impairment in a murine model of chronic kidney disease. Arterioscler. Thromb. Vasc. Biol. 40, 1239\u20131255 (2020).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"85950_CR30","doi-asserted-by":"publisher","first-page":"144","DOI":"10.3390\/nu13010144","volume":"13","author":"AK Duttaroy","year":"2021","unstructured":"Duttaroy, A. K. Role of gut microbiota and their metabolites on atherosclerosis, hypertension and human blood platelet function: a review. Nutrients 13, 144 (2021).","journal-title":"Nutrients"},{"key":"85950_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/9060143","volume":"2016","author":"SH Yun","year":"2016","unstructured":"Yun, S. H., Sim, E. H., Goh, R. Y., Park, J. I. & Han, J. Y. Platelet activation: The mechanisms and potential biomarkers. Biomed Res. Int. 2016, 1\u20136 (2016).","journal-title":"Biomed Res. Int."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-85950-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-85950-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-85950-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T05:44:35Z","timestamp":1670046275000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-85950-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,22]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["85950"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-85950-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,22]]},"assertion":[{"value":"16 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6580"}}